Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial

Abstract

ObjectivesData on costs associated with acute upper gastrointestinal bleeding (AUGIB) are scarce. We provide estimates of UK healthcare costs, indirect costs and health-related quality of life (HRQoL) for patients presenting to hospital with AUGIB.SettingSix UK university hospitals with >20 AUGIB admissions per month, >400 adult beds, 24 h endoscopy, and on-site access to intensive care and surgery.Participants936 patients aged ≥18 years, admitted with AUGIB, and enrolled between August 2012 and March 2013 in the TRIGGER trial of AUGIB comparing restrictive versus liberal red blood cell (RBC) transfusion thresholds.Primary and secondary outcome measuresHealthcare resource use during hospitalisation and postdischarge up to 28 days, unpaid informal care, time away from paid employment and HRQoL using the EuroQol EQ-5D at 28 days were measured prospectively. National unit costs were used to value resource use. Initial in-hospital treatment costs were upscaled to a UK level.ResultsMean initial in-hospital costs were £2458 (SE=£216) per patient. Inpatient bed days, endoscopy and RBC transfusions were key cost drivers. Postdischarge healthcare costs were £391 (£44) per patient. One-third of patients received unpaid informal care and the quarter in paid employment required time away from work. Mean HRQoL for survivors was 0.74. Annual initial inhospital treatment cost for all AUGIB cases in the UK was estimated to be £155.5 million, with exploratory analyses of the incremental costs of treating hospitalised patients developing AUGIB generating figures of between £143 million and £168 million.ConclusionsAUGIB is a large burden for UK hospitals with inpatient stay, endoscopy and RBC transfusions as the main cost drivers. It is anticipated that this work will enable quantification of the impact of cost reduction strategies in AUGIB and will inform economic analyses of novel or existing interventions for AUGIB.Trial registration numberISRCTN85757829 and NCT02105532.

Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study

“…34 Use of an accurate score within emergency departments or acute assessment units, to identify very low risk patients with upper gastrointestinal bleeding not requiring admission has clear benefits. Interestingly, sites varied in the proportion of very low risk patients defined by a Glasgow Blatchford score of 1 or less.…”

Better guidelines for better care: accounting for multimorbidity in clinical guidelines – structured examination of exemplar guidelines and health economic modelling

“…The model assumed that there was no cost burden associated with ADEs apart from the additional GP consultation, with the exception of patients who have a GI bleed, who were assumed to cost an additional £2850 because of the need for in-hospital and post-discharge care associated with bleeds. 229 The cost for each CHD event was calculated by multiplying the time spent in the health state with the per-day unit cost of the health state. These costs were adjusted according to whether the CHD health state was in its first year or subsequent follow-up years (see Table 30).…”

Continuity of Care Is Associated with Medical Costs and Inpatient Days in Children with Cerebral Palsy

“…Therefore, we did not take the emergency department visits into account in our results. In many diseases, such as acute myocardial infarction, gastrointestinal bleeding, acute kidney injury, and respiratory distress syndrome, outpatient medical costs are often lower than inpatient medical costs [37][38][39][40]. Our stratified analysis revealed that the low COCI group had more inpatient medical costs than the high COCI group.…”